Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

930 results about "Racemization" patented technology

In chemistry, Racemization is a conversion, by heat or by chemical reaction, of an optically active compound into an optically inactive form which half of the optically active substance becomes its mirror image (enantiomer) referred as racemic mixtures(i.e. contain equal amount of '+' and '-' forms) .If the racemization results in a mixture where the D and L enantiomers are present in equal quantities, the resulting sample is described as a racemic mixture or a racemate. Racemization can proceed through a number of different mechanisms, and it has particular significance in pharmacology as different enantiomers may have different pharmaceutical effects.

Fused ring compound and use thereof in KRAS inhibitor

A fused ring compound, a pharmaceutical composition comprising same, and the use thereof. The compound has a structure as represented by formula (I), or is a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a metabolite, a metabolic precursor, an isotope-substituted form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a co-crystal thereof. The compound can be used for treating one or more cancers caused by KRAS mutation.
Owner:CHENGDU HYPERWAY PHARM CO LTD +1

Fused ring compound and use

A fused ring compound, a pharmaceutical composition comprising same, and a use. The compound has a structure represented by formula (I) or a tautomer, mesomere, racemate, enantiomer, diastereomer or mixture thereof, metabolite, metabolic precursor, isotope substitution form, pharmaceutically acceptable salt, hydrate, solvate, polymorph or eutectic thereof. The compound can be used for treating a cancer caused by KRAS mutations, and said cancer is selected from one or more cancers caused by KRAS G12C, KRAS G12V, KRAS G12A and G12D mutations. In particular, the compound can serve as a G12D inhibitor and has relatively high inhibitory activity.
Owner:CHENGDU HYPERWAY PHARM CO LTD +1

Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.
Owner:AXCESS GLOBAL SCIENCES LLC

Multispecific bioconjugate linker and synthesis method thereof

The present application relates to a multi-specific bioconjugate linker and a method for synthesizing the same, and specifically to a compound or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof. The present application also relates to a method for preparing the compound and its use in tumor treatment.
Owner:PEKING UNIV

S-beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.
Owner:AXCESS GLOBAL SCIENCES LLC

BRD4 protein degradation agent compound as well as preparation method and application thereof

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof, which have better BRD4 inhibition and degradation effects as a drug, and can be used for preparing drugs related to BRD4 inhibition and degradation. And preventing and / or treating related diseases. # imgabs0 #
Owner:MIRACURE BIOTECHNOLOGY LTD

P53-Y220C selective small-molecule reactivator compound, pharmaceutical composition and application of p53-Y220C selective small-molecule reactivator compound

The invention provides a compound as shown in a formula (I), and a racemate, a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof. The compound has a good p53-Y220C mutant activation effect, can effectively recover the activity of the p53-Y220C mutant protein, and is used for treating tumor diseases containing the p53-Y220C mutant protein and preparing drugs for the diseases or the diseases. # imgabs0 #
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Preparation method of semaglutide side chain

The invention relates to the technical field of chemical synthesis, and particularly provides a preparation method of a semaglutide side chain, which comprises the following steps: step S1, carrying out reaction on octadecanedioic acid mono-tert-butyl ester and trifluoroacetic acid pentafluorophenyl ester to generate a first intermediate; s2, enabling the first intermediate to react with 1-tert-butyl L-glutamic acid to generate a second intermediate; s3, enabling the second intermediate to react with pentafluorophenyl trifluoroacetate to generate a third intermediate; and S4, carrying out an amidation reaction on the third intermediate and 17-amino-10-oxo-3, 6, 12, 15-tetraoxa-9-aza-heptadecanoic acid, so as to generate a semaglutide side chain, and carrying out an amidation reaction on the third intermediate and 17-amino-10-oxo-3, 6, 12, 15-tetraoxa-9-aza-heptadecanoic acid. According to the preparation method disclosed by the embodiment of the invention, the pentafluorophenyl trifluoroacetate is used as the condensation reagent for two times to activate the carboxylic acid, and the amidation reaction is carried out for two times to construct the amido bond after each activation, so that compared with the traditional carbodiimide and urea positive ion type condensation reagent, the chiral racemization in the condensation process can be effectively avoided, and the yield of the product is improved. The condensation chiral racemization impurity can be lower than 0.3%.
Owner:SUZHOU HIGHFINE BIOTECH

Lipase mutant and application thereof

The invention belongs to the field of biological pharmacy and biological conversion, and particularly relates to a lipase mutant and application thereof. The lipase CALB mutant disclosed by the invention is obtained by carrying out single-point mutation or combined mutation on the 40th site, the 134 site, the 154 site, the 189th site, the 278th site and the 281 site of an amino acid sequence as shown in SEQ ID NO.1. Compared with a wild type, the mutant has the advantage that the stereoselectivity is greatly improved when the mutant is used for catalyzing racemization 3-cyclohexene-1-methyl formate to produce (S)-3-cyclohexene-1-formic acid. Compared with a traditional chemical method for preparing (S)-3-cyclohexene-1-formic acid, the lipase CALB mutant provided by the invention is high in stereoselectivity, mild in reaction condition, environment-friendly, low in equipment requirement, capable of greatly reducing the production cost and wide in application prospect in industrial application.
Owner:ZHEJIANG UNIV OF TECH +1

Parkinson's disease specific plasma metabolism marker and application thereof

The invention belongs to the technical field of biomedicine, and discloses a Parkinson's disease specific plasma metabolism marker and application thereof.The plasma metabolism marker comprises uracil, kynurenine, phenolsulfonic acid, p-cresol, di-high gamma-linolenic acid, atorvastatin, 2-methoxybenzoic acid, carabicycline, nitrogen hydroxyl 2-amino-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5- The invention relates to an anti-inflammatory agent which is prepared from 2, 8-dimethylimidazo quinoxaline, dihydroxy phenethyl alcohol O-sulfate, racemization-4-hydroxy-4-O-(beta-D-glucuronate)-all-trans retinol acetate, fructosyl valine, thiaxanthene and acetylpyridine methanol. It is proved for the first time that the 14 plasma metabolites are associated with the Parkinson's disease, a Parkinson's disease prediction method is constructed based on the markers, the prediction result is reliable, and a new way is provided for diagnosis of the Parkinson's disease.
Owner:襄阳市第一人民医院 +1

S-beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.
Owner:AXCESS GLOBAL SCIENCES LLC

Use of s-beta-hydroxybutyrate compounds for induction and maintenance of flow

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.
Owner:AXCESS GLOBAL SCIENCES LLC

PRMT5 inhibitor and preparation method therefor

The present invention relates to the field of medicine, and in particular to a PRMT5 inhibitor, as well as a preparation method therefor and a use thereof. The PRMT5 inhibitor is a compound as shown in formula (I), an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, a polymorph, a prodrug, an isotope variant, or a pharmaceutically acceptable salt thereof. The present invention has better activity, selectivity, pharmacokinetic characteristics, safety or a wider treatment window.
Owner:BEIJING TIDE PHARMACEUTICAL CO LTD

Method for synthesizing axial chiral N-aryl quinazolinone through photo-oxidation reduction catalytic deracemization

The invention discloses a method for synthesizing axial chiral N-aryl quinazolinone through photo-oxidation reduction catalysis deracemization, and belongs to the field of organic synthesis.The method comprises the steps that raceme shown in the formula I serves as a raw material, Ir [dF (CF3) ppy] 2 (dtbbpy) PF6 serves as a photosensitizer, spiro chiral phosphonic acid CPA serves as a chiral catalyst in an organic solvent, the reaction is complete at the room temperature to-40 DEG C under visible light irradiation, and the axial chiral N-aryl quinazolinone is obtained. The preparation method comprises the following steps: taking a compound 1 as a raw material, separating and purifying to obtain a central chiral compound 1, completely reacting the central chiral compound 1 in an organic solvent B by taking DDQ as an oxidizing agent at-30 DEG C to-40 DEG C, and performing post-treatment to obtain axial chiral N-aryl quinazolinone 2, # imgabs 0 # imgabs 1 #. The axial chiral 2-aza-aryl functionalized quinazolinone which has important value but is difficult to obtain is efficiently synthesized. The method has the advantages that the method is simple, the substrate range is wide, enrichment of 2, 3-dihydroquinazoline-4 (1H)-ketone enantiomers is achieved through deracemization, and then the enantiomers are simply oxidized to achieve assembly of the N-3 axis and the unreported N-1 axis.
Owner:HENAN UNIVERSITY OF TECHNOLOGY

Organic molecule modified gold nanocluster as well as preparation method and application thereof

The invention relates to the technical field of nano materials, and provides an organic molecule modified gold nanocluster as well as a preparation method and application thereof. The organic molecule modified gold nanocluster provided by the invention comprises a gold nanocluster and an organic molecule modified on the gold nanocluster, and the organic molecule is one or more of L-penicillamine, D-penicillamine, racemic penicillamine, L-cysteine, D-cysteine and racemic cysteine. According to the preparation method disclosed by the invention, the gold nanoclusters are modified by organic molecules, and the modified gold nanoclusters have a good inhibition effect on DAAO; in addition, the DAAO inhibition effect of the gold nanocluster modified by the L-penicillamine and the L-cysteine is the best, and it is indicated that the DAAO inhibition effect is related to the chiral structure of organic molecules. The invention further provides a preparation method of the gold nanocluster modified by the organic molecules, and the preparation method provided by the invention is simple in step and easy to operate.
Owner:SHANGHAI NORMAL UNIVERSITY

Pyrrolo [2, 1-f] [1, 2, 4] triazine compound, preparation method and application thereof, intermediate, pharmaceutical composition and cGAS agonist

The invention discloses a compound as shown in a formula (I), and / or pharmaceutically acceptable salts thereof, and / or a raceme mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and belongs to the technical field of medicines. The invention also discloses a pharmaceutical composition containing the compound as shown in the formula (I), and the compound as shown in the formula (I) and / or a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and / or the pharmaceutical composition, a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof. The invention further discloses application of the cGAS agonist in preparation of the cGAS agonist and a medicament for treating diseases responding to activation of the cGAS-STING signal channel.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT

Method for preparing raceme from enantiomer of fenerenone or intermediate thereof

The invention provides a method for preparing raceme from an enantiomer of fennerenone or an intermediate thereof, which comprises the following step: reacting a compound Ia in the presence of alkali and a photocatalyst under illumination to generate a compound I. The compound I is shown in the description. The method for preparing the racemate of the fenerenone or the intermediate of the fenerenone is low in cost, less in environmental pollution, high in yield, high in safety and suitable for industrial large-scale production. # imgabs0 #
Owner:AURISCO PHARMACEUTICAL CO LTD

Preparation method of high-efficiency selective antagonist BQ-788

The invention provides a preparation method of an efficient selective antagonist BQ-788, and relates to the technical field of preparation of antagonists. A solid-liquid combination method is adopted for synthesis, due to the fact that dimethyl dialkanoate on a side chain of tryptophan (DTrp) is difficult, Fmoc-DTrp (CO2Me)-OH is obtained through liquid-phase synthesis, p-methoxybenzyl is selected for protecting carboxyl in the synthesis process, the carboxyl can be removed through trifluoroacetic acid subsequently, and the risk that an indole ring of tryptophan is reduced due to hydrogenation can be successfully avoided. According to the present invention, by using the solid phase synthesis method, the fragment can be rapidly and efficiently obtained, the racemization problem during the condensation process can be effectively avoided, the urea is formed on the solid phase, the operation is simple and convenient, the hydrogen and the diphosgene are not used during the preparation process, the production is safe, the obtained product has characteristics of high yield and high purity, and the preparation steps are less.
Owner:HANGZHOU TAIJIA BIOTECH CO LTD

FGFR2 / 3 selective inhibitor, pharmaceutical composition and use thereof

Provided are a compound represented by formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, an oxynitride, a solvate, a polymorph, a metabolite, an ester, a prodrug, or a pharmaceutically acceptable salt thereof. The compound has a good FGFR2 / 3 inhibitory effect, and can be used for treating or preventing FGFR2 / 3-mediated disorders and diseases, and preparing drugs for treating or preventing such disorders and diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Chemical synthesis method and use method of ergothioneine

The invention provides a chemical synthesis method of ergothioneine in different optical forms (such as L-form or D-form or any mixture thereof). Another aspect of the invention relates to a composition comprising a non-racemic mixture of L-ergothioneine and D-ergothioneine.
Owner:NANJING NUTRABUILDING BIO TECH CO LTD

Cyclohexene formate esterase, mutant and application of cyclohexene formate esterase in production of (S)-3-cyclohexene-1-formic acid

The invention discloses cyclohexene formate esterase, a mutant of cyclohexene formate esterase and application of cyclohexene formate esterase in production of (S)-3-cyclohexene-1-formic acid. According to the cyclohexene formate esterase and the mutant disclosed by the invention, 100-400g / L of racemic 3-cyclohexene-1-methyl formate can be split by taking wet thalli subjected to induced expression or crude enzyme liquid obtained by ultrasonically crushing the wet thalli as a catalyst, so that (S)-3-cyclohexene-1-formic acid with chemical purity and optical purity reaching 99% or above is synthesized. The enzyme activity of the cyclohexene formate esterase mutant provided by the invention is further improved, the reaction time and the catalyst dosage are obviously reduced compared with those of a substrate with the same catalysis concentration before mutation, the reaction condition is mild, the operation is relatively simple and convenient, and the cyclohexene formate esterase mutant has a very good industrial application prospect.
Owner:ZHEJIANG UNIV OF TECH

Method for preparing finerenone and intermediate thereof

Disclosed is a method for preparing a finerenone intermediate compound of formula (I) from a diastereomeric tartrate by means of racemic resolution. A compound of formula I having an ee value higher than 99.5% can be obtained. The preparation method provided has mild reaction conditions, simple post-treatment, and no special reagents required, and is suitable for industrial production.
Owner:AURISCO PHARMACEUTICAL CO LTD

Synthesis method of tilpotide

The synthesis method comprises the following steps: firstly, respectively synthesizing a fragment I (1-13), a fragment II (14-21) and a fragment III (22-39), then synthesizing a fragment (14-39) in a liquid phase by using the fragment II (14-21) and the fragment III (22-39), and finally, condensing, cracking and purifying the fragment I (1-13) and the fragment (14-39) in the liquid phase to prepare the tilpotide. According to the invention, synthesis is carried out through three fragments, so that the synthesis steps are simplified, the racemization problem is avoided, + / -Gly impurities are reduced, and DKP side reaction is avoided and reduced, thereby improving the whole yield.
Owner:HYBIO PHARMA

HPK1 degradation agent and use thereof in field of medicine

PCT designated stage expiredWO2025103489A1Organic active ingredientsOrganic chemistryDiseaseMetabolite
An HPK1 degradation agent and use thereof in the field of medicine. The invention specifically relates to a compound as shown in a general formula (I) or a stereoisomer, a racemate, a tautomer, a deuterated substance, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic thereof, and an intermediate thereof, and the use thereof in inhibiting or degrading HPK1-related diseases such as cancer. B-L-K (I)
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD

A method for synthesizing rasagiline in a microfluidic field

The present invention discloses a method for synthesizing rasagiline in a microfluidic field. The method is based on a double enzyme hydrogenation cascade reaction, which efficiently converts racemic alcohol into enantiomeric amines, realizes the direct synthesis of chiral amines, and has high atom economy and reaction efficiency. Racemic 1-indanol is completely oxidized to generate 1-indanone by alcohol dehydrogenase catalysis, and the cofactor NADP+ is reduced to NADPH to provide the required reducing power for subsequent reactions; using ( R )-selective reductive amino enzyme catalyzes the reductive amination reaction of 1-indanone to generate the target product rasagiline. The present invention adopts a dual enzyme synergistic catalytic strategy to successfully achieve the efficient conversion from racemic alcohol to chiral amine, has the advantages of mild reaction conditions, green sustainability, high product yield and optical purity, and provides a new efficient, economical and environmentally friendly way for the synthesis of rasagiline.
Owner:NANJING TECH UNIV

Gadolinium chelate compounds for use in magnetic resonance imaging

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.
Owner:BAYER PHARMA AG

An efficient preparation method of triptorelin acetate

The present invention belongs to the technical field of pharmaceutical synthesis, and particularly relates to a method for efficiently preparing triptorelin acetate. The present invention adopts a fragment condensation method combining solid phase and liquid phase, prepares fragments 1-7 by solid phase method, prepares fragments 8-10 by liquid phase method, then condenses fragments 1-7 and fragments 8-10 by solid phase method to obtain triptorelin 10-peptide resin, and finally cleaves the resin and purifies it to obtain triptorelin acetate. This method can effectively avoid the racemization of His and Pyr, significantly reduce the D-His2-triptorelin impurity, and obtain triptorelin acetate with a purity of more than 99.9% at a total yield of up to 65%.
Owner:LUNAN NEW TIME BIOTECHNICAL CO LTD